Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-TD-nsIL12 for Progressive Pediatric DIPG
NCT05717699Phase 1Recruiting
- Sponsor
- Capital Medical University
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ad-TD-nsIL12 in diffuse intrinsic pontine glioma (DIPG), sponsored by Capital Medical University. Primary endpoint: Safety of Ad-TD-nsIL12 intratumoral injection at 3 months. Started Jan 2023; status: recruiting.
02
Drugs
Ad-TD-nsIL12
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT05717699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717699.